| BIOGEN INC. DL -,0005 | 229,900 / +0,02% |
| 日期/时间 | 19.01. / 15:40 |
| 涨跌。 / 涨跌。(%) | 0,050 / +0,02% |
| Bid | 229,900 |
| Ask | 230,250 |
| 打开 | 229,850 |
| 以往收市 | 229,850 |
| 高 | 231,200 |
| 低 | 227,300 |
| 成交量 [EUR] | - |
| 成交量 [Units] | |
| Price fixings | 1081 |
| ISIN | US09062X1037 |
| 符号 | IDP |
| 交易所 | Lang & Schwarz |
| 类型 | 股票 |
所有交易
| 交易所 | 最后的 | 成交量 | |
|---|---|---|---|
| NASDAQ | 279,2300 |  |
69.689 |
| IEX | 279,28 | |
7.777 |
| Cboe US | 278,73 |  |
1.659 |
| TradeGate | 229,550 | |
930 |
| Xetra | 229,65 | |
705 |
| London Inter.. | 279,01 | |
581 |
| Vienna Globa.. | 228,65 | |
274 |
| Frankfurt | 229,2500 | |
100 |
| gettex | 229,700 | |
100 |
| Hannover | 230,05 | |
40 |
| Düsseldorf | 229,00 | |
9 |
| München | 230,80 | |
0 |
| Hamburg | 230,40 | |
0 |
| Berlin | 229,65 | |
0 |
| Lang & Schwa.. | 229,900 | |
|
| Stuttgart | 230,850 | |
|
| Mexico | 5.488,00 | |
758 |
新闻
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
11.01.2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
08.01.2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
21.12.2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
17.12.2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
10.12.2020 / 04:30 - GlobeNewswire